--- title: "Recursion Pharmaceuticals Metrics Guide" description: "Recursion Pharmaceuticals Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained." canonical: https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/financial-metrics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Recursion Pharmaceuticals Inc. Financial Metrics Guide ## Direct Answer > Recursion Pharmaceuticals Inc. reported revenue of $75 million for the fiscal year ended December 31, 2025, with an operating margin of -867.9% and net income of -$645 million, according to its SEC filings. Revenue grew 26.9% from the prior year. ## What Are Recursion Pharmaceuticals Inc.'s Key Financial Figures? | Fiscal year | FY2025ended December 31, 2025 | FY2024ended December 31, 2024 | FY2023ended December 31, 2023 | FY2022ended December 31, 2022 | | --- | --- | --- | --- | --- | | Revenue | $75 million | $59 million | $45 million | $40 million | | Operating income | -$648 million | -$479 million | -$350 million | -$246 million | | Operating margin | -867.9% | -814.1% | -785.3% | -616.7% | | Net income | -$645 million | -$464 million | -$328 million | -$239 million | | Net margin | -863.4% | -788.0% | -736.0% | -601.0% | | Operating cash flow | -$372 million | -$359 million | -$288 million | -$84 million | | Capital expenditures | $6 million | $14 million | $12 million | $37 million | | Free cash flow | -$378 million | -$373 million | -$300 million | -$121 million | Operating margin narrowed by 53.8 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$378 million against net income of -$645 million; cash generation covered reported earnings. ![Bar chart of Recursion Pharmaceuticals Inc. revenue, operating income, net income for fiscal 2022 to 2025. In fiscal 2025, revenue was $75 million, operating income negative $648 million and net income negative $645 million.](https://www.getswoopr.com/images/charts/recursion-pharmaceuticals-inc-metrics-revenue-profit.webp) *Recursion Pharmaceuticals Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.* ![Line chart of Recursion Pharmaceuticals Inc. operating margin and net margin for fiscal 2022 to 2025. In fiscal 2025, operating margin was -867.9% and net margin was -863.4%.](https://www.getswoopr.com/images/charts/recursion-pharmaceuticals-inc-metrics-margins.webp) *Recursion Pharmaceuticals Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.* ![Bar chart of Recursion Pharmaceuticals Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2025. In fiscal 2025, operating cash flow was negative $372 million, capital expenditures was $6 million, free cash flow was negative $378 million.](https://www.getswoopr.com/images/charts/recursion-pharmaceuticals-inc-metrics-cash-flow.webp) *Recursion Pharmaceuticals Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.* ## What Does Recursion Pharmaceuticals Inc.'s Balance Sheet Show? | Cash and cash equivalents | $743 million | | --- | --- | | Long-term debt | $10 million | | Total assets | $1.5 billion | | Total liabilities | $343 million | | Shareholders' equity | $1.1 billion | | Current ratio | 5.5x | Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions. ## Where These Numbers Come From Every figure on this page is a value Recursion Pharmaceuticals Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001601830-26-000039 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What was Recursion Pharmaceuticals Inc.'s revenue in fiscal 2025? Recursion Pharmaceuticals Inc. reported revenue of $75 million for the fiscal year ended December 31, 2025, according to its SEC filings. ### What is Recursion Pharmaceuticals Inc.'s operating margin? Recursion Pharmaceuticals Inc.'s operating margin was -867.9% in fiscal 2025: operating income of -$648 million on revenue of $75 million. ### How much free cash flow did Recursion Pharmaceuticals Inc. generate? Operating cash flow of -$372 million less capital expenditures of $6 million gives free cash flow of -$378 million for fiscal 2025. ## References - [SEC EDGAR: RECURSION PHARMACEUTICALS, INC. Form 10-K filed February 25, 2026](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm) - [SEC EDGAR: RECURSION PHARMACEUTICALS, INC. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1601830&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Recursion Pharmaceuticals Inc. company dossier](https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/) - [Recursion Pharmaceuticals Inc. financial metrics](https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/financial-metrics/) - [Recursion Pharmaceuticals Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/risks-monitoring/) - [Recursion Pharmaceuticals Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).